NGM Biopharmaceuticals has been granted a patent for binding agents, such as antibodies, that specifically bind to complement component C3, including human C3. The patent also covers related polynucleotides and vectors encoding the binding agents and cells comprising them. GlobalData’s report on NGM Biopharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights NGM Biopharmaceuticals Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on NGM Biopharmaceuticals, Human telomerase RT biomarker was a key innovation area identified from patents. NGM Biopharmaceuticals's grant share as of September 2023 was 32%. Grant share is based on the ratio of number of grants to total number of patents.

Patent granted for antibodies that bind human complement component c3

Source: United States Patent and Trademark Office (USPTO). Credit: NGM Biopharmaceuticals Inc

A recently granted patent (Publication Number: US11767359B2) discloses an isolated polynucleotide that encodes an antibody specifically designed to bind to human complement component C3. The antibody consists of a heavy chain variable region (VH) and a light chain variable region (VL), both of which have specific amino acid sequences. The VH region includes three complementarity determining regions (CDRs) - CDR1, CDR2, and CDR3, while the VL region includes VL CDR1, VL CDR2, and VL CDR3. The amino acid sequences for these regions are provided in the patent.

The patent also describes various variations of the isolated polynucleotide, including different combinations of amino acid sequences for the CDRs. These variations allow for the customization of the antibody's binding properties. Additionally, the patent specifies that the antibody can be of different types, such as chimeric, humanized, bispecific, multispecific, Fab, Fab', F(ab'),2, Fv, scFv, (scFv)2, single chain antibody, dual variable region antibody, or diabody.

Furthermore, the patent includes claims related to the sequence identity of the VH and VL regions. It states that the VH region can have at least 80% or 90% sequence identity to the provided amino acid sequence, and the VL region can have at least 80% or 90% sequence identity. The patent also mentions that the antibody can be an IgG1, IgG2, or IgG4 antibody.

Overall, this patent presents an isolated polynucleotide encoding an antibody that specifically binds to human complement component C3. The patent provides various options for customizing the antibody's binding properties and describes different types of antibodies that can be generated using the disclosed polynucleotide.

To know more about GlobalData’s detailed insights on NGM Biopharmaceuticals, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies